Literature DB >> 12890240

Emergency embolization of spontaneous ruptured hepatocellular carcinoma: correlation between survival and Child-Pugh classification.

K Y Lau1, T P Wong, W W C Wong, L T H Tan, J K W Chan, A S L Lee.   

Abstract

From February 1994 to April 2000, 29 emergency gelfoam embolizations for spontaneous ruptured hepatocellular carcinoma (HCC) performed in 28 patients were retrospectively reviewed. There were 11 patients in Child's A, 11 in Child's B and six in Child's C classification of cirrhosis. The duration of the procedure, artery embolized and complications were reviewed, and the Child-Pugh classification of each patient was correlated with their mean survival period. Embolization was done in 12 right hepatic arteries, two left hepatic arteries and 15 proper hepatic arteries. In one patient, the left hepatic artery was embolized initially but the proper hepatic artery was also embolized because another subcapsular liver tumour was found after reviewing the preangiogram CT scan. The entire procedure took 40-170 min (mean = 86 min) with no periprocedural complication. Following embolization, the mean survival period for Child's A class was 218.3 days, Child's B class was 83.4 days and Child's C class was 11.0 days. Transcatheter embolization is an effective treatment to arrest bleeding in spontaneous ruptured HCC. Patients with Child's A class cirrhosis have the longest survival. Selective embolization of either the right or the left hepatic artery alone carries the potential risk of missing multifocal HCC that might not be easily appreciated during angiography.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890240     DOI: 10.1046/j.1440-1673.2003.01168.x

Source DB:  PubMed          Journal:  Australas Radiol        ISSN: 0004-8461


  7 in total

1.  Complications of embolization.

Authors:  José I Bilbao; Antonio Martínez-Cuesta; Femín Urtasun; Octavio Cosín
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

Review 2.  Rupture of Hepatocellular Carcinoma: A Review of Literature.

Authors:  Srimanta K Sahu; Yogesh K Chawla; Radha K Dhiman; Virendra Singh; Ajay Duseja; Sunil Taneja; Naveen Kalra; Ujjwal Gorsi
Journal:  J Clin Exp Hepatol       Date:  2018-04-26

3.  Survival outcome of patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization.

Authors:  Young-Joo Jin; Jin-Woo Lee; Seoung-Wook Park; Jung Il Lee; Don Haeng Lee; Young Soo Kim; Soon Gu Cho; Yong Sun Jeon; Kun Young Lee; Seung-Ik Ahn
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

4.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

5.  Liver radiofrequency ablation as emergency treatment for a ruptured hepatocellular carcinoma: a case report.

Authors:  Alessandra Bertacco; Francesco D'Amico; Maurizio Romano; Michele Finotti; Alessandro Vitale; Umberto Cillo
Journal:  J Med Case Rep       Date:  2017-03-01

6.  Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study.

Authors:  Hiroyuki Kirikoshi; Satoru Saito; Masato Yoneda; Koji Fujita; Hironori Mawatari; Takashi Uchiyama; Takuma Higurashi; Kento Imajo; Takashi Sakaguchi; Kazuhiro Atsukawa; Aya Sawabe; Akira Kanesaki; Hirokazu Takahashi; Yasunobu Abe; Masahiko Inamori; Noritoshi Kobayashi; Kensuke Kubota; Norio Ueno; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2009-04-30       Impact factor: 3.067

7.  Impact of spontaneous tumor rupture on prognosis of patients with T4 hepatocellular carcinoma.

Authors:  Wen-Hui Chan; Chien-Fu Hung; Kuang-Tse Pan; Kar-Wai Lui; Yu-Ting Huang; Shen-Yen Lin; Yang-Yu Lin; Tsung-Han Wu; Ming-Chin Yu
Journal:  J Surg Oncol       Date:  2016-04-07       Impact factor: 3.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.